$2.52
+0.06
(+2.6%)▲
1.98%
Downside
Day's Volatility :4.26%
Upside
2.33%
55.16%
Downside
52 Weeks Volatility :86.05%
Upside
68.89%
Period | Im Cannabis Corp | Russel 2000 | Index (Russel 2000) |
---|---|---|---|
3 Months | -26.22% | 0.0% | 0.0% |
6 Months | 24.76% | 0.0% | 0.0% |
1 Year | -48.9% | 0.0% | 0.0% |
3 Years | -99.21% | -20.2% | -20.2% |
Market Capitalization | 5.0M |
Book Value | $4.26 |
Earnings Per Share (EPS) | -4.84 |
Wall Street Target Price | 5.95 |
Profit Margin | -30.04% |
Operating Margin TTM | -23.85% |
Return On Assets TTM | -14.96% |
Return On Equity TTM | -93.52% |
Revenue TTM | 48.3M |
Revenue Per Share TTM | 21.74 |
Quarterly Revenue Growth YOY | -3.6999999999999997% |
Gross Profit TTM | 9.2M |
EBITDA | -9.3M |
Diluted Eps TTM | -4.84 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.3 |
EPS Estimate Next Year | -1.87 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 136.11%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.8M | - |
Net Income | 1.2M | ↓ 1446.72% |
Net Profit Margin | 32.38% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 6.9M | ↑ 74.6% |
Net Income | -5.7M | ↓ 540.82% |
Net Profit Margin | -81.76% | ↓ 114.14% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 12.5M | ↑ 75.12% |
Net Income | -22.5M | ↑ 287.3% |
Net Profit Margin | -180.83% | ↓ 99.07% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 42.6M | ↑ 241.72% |
Net Income | -14.5M | ↓ 35.55% |
Net Profit Margin | -34.1% | ↑ 146.73% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 40.1M | ↑ 0.06% |
Net Income | -18.4M | ↑ 34.58% |
Net Profit Margin | -45.87% | ↓ 11.77% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 48.8M | ↓ 10.18% |
Net Income | -9.5M | ↓ 61.89% |
Net Profit Margin | -19.46% | ↑ 26.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.7M | ↑ 2.05% |
Net Income | -7.1M | ↑ 112.95% |
Net Profit Margin | -66.74% | ↓ 34.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.7M | ↓ 8.91% |
Net Income | 31.8K | ↓ 100.45% |
Net Profit Margin | 0.33% | ↑ 67.07% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.0M | ↑ 0.26% |
Net Income | -2.8M | ↓ 8718.6% |
Net Profit Margin | -28.06% | ↓ 28.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.1M | ↑ 188.53% |
Net Income | -6.2M | ↑ 67.54% |
Net Profit Margin | -16.29% | ↑ 11.77% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.7M | ↓ 71.93% |
Net Income | -3.3M | ↓ 47.03% |
Net Profit Margin | -30.74% | ↓ 14.45% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.9M | ↑ 12.76% |
Net Income | -4.2M | ↑ 70.96% |
Net Profit Margin | -46.61% | ↓ 15.87% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 27.2K | ↑ 304.71% |
Total Liabilities | 184.7K | ↓ 46.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 23.7M | ↑ 83390.53% |
Total Liabilities | 3.7M | ↑ 1801.45% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 29.9M | ↑ 23.38% |
Total Liabilities | 20.0M | ↑ 433.04% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 225.5M | ↑ 653.98% |
Total Liabilities | 64.7M | ↑ 223.23% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 44.8M | ↓ 78.89% |
Total Liabilities | 27.2M | ↓ 55.27% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 48.8M | ↓ 19.55% |
Total Liabilities | 35.1M | ↓ 4.79% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 44.8M | ↓ 52.99% |
Total Liabilities | 27.2M | ↓ 49.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 42.0M | ↓ 6.4% |
Total Liabilities | 23.8M | ↓ 12.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 42.1M | ↓ 1.83% |
Total Liabilities | 25.8M | ↑ 6.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.4M | ↓ 6.07% |
Total Liabilities | 32.6M | ↓ 4.8% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 48.8M | ↓ 6.78% |
Total Liabilities | 35.1M | ↑ 7.8% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 30.4M | ↓ 15.78% |
Total Liabilities | 24.2M | ↓ 6.69% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.0K | ↓ 51.89% |
Investing Cash Flow | -535.2K | ↑ 71.13% |
Financing Cash Flow | 58.2K | ↓ 20.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.6M | ↑ 12783.21% |
Investing Cash Flow | -2.9M | ↑ 417.83% |
Financing Cash Flow | 13.1M | ↑ 21420.89% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.2M | ↑ 32.89% |
Investing Cash Flow | -3.2M | ↑ 7.95% |
Financing Cash Flow | 5.3M | ↓ 60.47% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.0M | ↑ 334.04% |
Investing Cash Flow | -7.1M | ↑ 121.15% |
Financing Cash Flow | 38.2M | ↑ 623.01% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↓ 63.23% |
Investing Cash Flow | -1.0M | ↓ 84.38% |
Financing Cash Flow | 3.5M | ↓ 90.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.9M | ↓ 411.9% |
Investing Cash Flow | -429.9K | ↑ 211.23% |
Financing Cash Flow | 1.4M | ↓ 144.01% |
Sell
Neutral
Buy
Im Cannabis Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Im Cannabis Corp | -12.91% | 24.76% | -48.9% | -99.21% | -99.56% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Im Cannabis Corp | NA | NA | NA | -4.3 | -0.94 | -0.15 | NA | 4.26 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Im Cannabis Corp | Buy | $5.0M | -99.56% | NA | -30.04% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Im Cannabis Corp
Revenue is up for the last 2 quarters, 10.69M → 12.06M (in $), with an average increase of 11.3% per quarter
Netprofit is down for the last 2 quarters, -3.28M → -5.62M (in $), with an average decrease of 71.0% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 94.4%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 151.8%
AdvisorShares Investments, LLC
Black Maple Capital Management LP
BMO Capital Markets Corp.
Bank of Montreal
Renaissance Technologies Corp
Virtu Financial LLC
premium medical cannabis products for global consumers – im cannabis (imc) is one of the world's pioneering medical-grade cannabis companies, with operations in israel, across europe, and canada. over the past decade, imc has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as 'roma', 'tel aviv' and 'london'. in europe, imc has established a fully operational, vertically integrated medical cannabis business, spearheaded by its eu-gmp certified distribution arm in germany and augmented by strategic alliances with certified pan-eugmp certified suppliers. to this end, imc has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. imc further intends to leverage its expertise in israel in order to bolster its res
Organization | Im Cannabis Corp |
Employees | 95 |
CEO | Mr. Marc Lustig M.B.A., M.Sc. |
Industry | Healthcare |